Vismodegib in the treatment of basal cell carcinoma -Polish clinical experience in the frame of therapeutic program ABSTRACT Introduction. Vismodegib is a small-molecule inhibitor of the sonic hedgehog pathway, registered for the treatment of patients with metastatic or locally advanced basal cell carcinoma, who were disqualified from surgical excision or radiotherapy. The full treatment refund from the National Health Fund has been available in Poland since 1 st January 2018. The aim of the study was to analyse the frequency of occurrence of adverse events based on CTCAE and the treatment results based on the RECIST 1.1 criteria, in a group of patients treated for six or 12 months with vismodegib.
Introduction
Based on data from the National Cancer Registry, the incidence of skin cancer in the Polish population in 2010 was 6.8% in men and 7.5% in women [1] . The standardised rate for individuals aged 65 years or older was 146.4 and 96.8 in men and women, respectively. The number of registered skin cancers in 2010 was over 10,000. The exact skin cancer incidence in Poland is not known due to insufficient reporting to the National Cancer Registry. A good reference for the European population may be a Danish study, which revealed basal cell carcinoma (BCC) incidence in 2005 accounting for 6074 cases/100,000 among women aged 65 years or older and 6347 cases/100,000 among men, with a 5-6-fold increase in morbidity between 1973 and 2008. The authors of the study predict, based on current statistical data, that by 2020 the incidence in the group over 65 years old will be 16,282/100,000 and 20,019/100,000 in women in men, respectively [2] .
Basal cell carcinoma is slow growing, slightly and locally aggressive tumour. The metastatic rate is estimated to be around 0.0028-0.55% [3] . It occurs most frequently in patients over 65 years of age (constituting over 95% of cases) and is located mainly in the facial area, 30% of which are within the nose, 7% around the orbit, and about 6% of lesions concern the ear. The occurrence of one BCC is associated with a 40% risk of occurrence a second one in the next five years; if there was more than one BCC, the risk of the next lesion increases to 75% [2, 3] .
Vismodegib is a small-molecule drug belonging to the group of hedgehog pathway (Hh) inhibitors, which has been registered by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), based on results of the ERIVANCE and STEVIE studies for the treatment of patients with symptomatic metastatic basal cell carcinoma (mBCC) or locally advanced basal cell carcinoma (laBCC), who are ineligible for surgery or radiotherapy [4] [5] [6] . Since 1 st January 2017, vismodegib has been accessible to patients in Poland as part of a drug program reimbursed by the National Health Fund (NFZ). The final qualification of patients for the program is carried out by the Coordination Team for the Treatment of Basal Cell Skin Cancer, appointed by the President of the NFZ. During the period from 1 st August 2017 to 30 th September 2018 a total of 78 patients started treatment with vismodegib in Poland.
Aim of work
The aim of the study was to analyse groups of patients qualified for vismodegib therapy, to assess the frequency of adverse events with determination of their severity according to Common Terminology Criteria for Adverse Events (CTCAE), and to summarise the outcomes after six and 12 months. Data regarding patients came from three centres: 
Patients and methods
The analysis included 42 patients (30 male and 12 female) aged 33-87 years (mean 63.2). All patients were qualified to the program, according to inclusion criteria, due to the presence of histopathologically confirmed, locally advanced basal cell carcinoma; in seven out of 42 patients the additional criterion for inclusion was coexisting metastases (CNS 1/9, liver 1/9, lung 5/9, lymph nodes 1/9, and bones 1/9). In addition, 5/42 patients were diagnosed with Gorlin-Goltz syndrome (GGS). At qualification for participation in the program, all patients were disqualified from possible further surgical treatment and radiotherapy. Of the 42 patients, 27 had previously been treated surgically, 16 had had radiotherapy, and four had received chemotherapy; 2/42 patients had been unsuccessfully treated with three and 13/42 patients with two of the above methods. All patients met the remaining criteria for participation in the program, i.e. regarding laboratory tests, imaging evaluation, and performance status (PS) based on the Eastern Cooperative Oncology Group (ECOG), in accordance with the NFZ guidelines [7, 8] . The drug in the form of capsules was taken orally in a single daily dose of 150 mg. Treatment was continued until the exclusion criteria were met: documented progression during the use of the drug, the occurrence of hypersensitivity symptoms to vismodegib or any of the excipients, the occurrence of an adverse event preventing further treatment, or patient withdrawal. The contraindication to vismodegib treatment included pregnancy and breastfeeding. Due to the teratogenicity of the drug it was necessary to use effective contraception during the therapy and after its completion (women for two years and men for two months). The duration of treatment in the 42 patients ranged between three weeks and 68 months. The analysis of the occurrence of individual adverse reactions and their severity according to CT-CAE version 5.0 included 42 patients [9] . The patients were carefully monitored every 2-3 months based on medical history, physical examination, laboratory tests, photographic documentation, and imaging examinations [8] . Response to treatment was assessed according to RECIST 1.1 after six and 12 months in 29/42 and 17/42 patients, respectively [10] . The reason for treatment discontinuation and the time to progression in patients who did not respond to treatment were also shown. A summary of all data collected in the analysed population is presented in Table 1 . 
Results
The outcome summary of 42 patients is presented in Table 2 and 3. At the time of writing, only 29 patients have completed 6 months of therapy, and 17 of them have completed 12 months. In the latter group there were three patients with metastases. The duration of treatment differed significantly and was between 0.75 and 68 months, with the median duration of treatment 8.25 months. Among patients who were treated for less than 12 months the median follow-up was 8 months, while in patients treated for more than 12 months the median follow-up was 14 months. Table 4 presents the results of treatment effectiveness after 6 and 12 months in the study group in comparison with the results of the ERIVANCE and STEVIE studies as well as the EAS (expanded access study). However, the significant differences in the sizes of individual groups of patients, as well as the percentage of mBCC in the study group and the duration of treatment, should be highlighted [4, 5, 11] . Table 5 presents a summary of occurrence of adverse reactions among 42 patients, as compared to the ERIV-ANCE, STEVIE, and EAS studies. It should be added that whilst 7 out of 42 patients discontinued treatment due to disease progression, there was no case of discontinuation of treatment due to adverse events, which occurred in a total of 73.8% of patients; however, 74.3% of AEs had G1 and 23% had G2 intensity according to CTCAE version 5.0. It should also be concluded that the frequency of reported adverse reactions both in total and in relation to individual signs/symptoms was significantly lower than demonstrated in the ERIVANCE, STEVIE, and EAS studies [4, 5, 11 ].
Discussion
The efficacy and safety of vismodegib treatment have been confirmed in the multicentre, non-randomised, international ERIVANCE study, the results of which were published in 2012 [4] . The study group included 104 patients with locally advanced (laBCC; 71/104, in total 63 patients were included in the final analysis) and metastatic basal cell carcinoma (mBCC; 33/104). The duration of treatment was 0.7-18.7 months, and the median was 10 months. The objective response rate (ORR) in the first group was 43% (95% CI, 31-56, p < 0.001) and 30% in the second group (95% CI; 16-48; p = 0.001), while the response rate (RR) was 21%. Disease stabilisation (SD) was obtained in 64% and 38% of patients, respectively, while progression of disease (PD) was found in 3% and 13% of patients, respectively. Median duration of response (DOR) in both groups was 7.6 months, and the median progression-free survival (PFS) was 9.5 months. The results of this study led to the approval of vismodegib by the FDA and EMA for the treatment of advanced BCC patients. In 2015 Lacouture et al. published the preliminary results of a prospective multicentre observational study planned for eight years to assess efficacy and safety in about 750 patients with advanced BCC stratified to three treatment groups: C1 -patients previously not treated with vismodegib, who will receive vismodegib, C2 -patients previously treated with vismodegib, who will undergo surgical treatment, and C3 -patients with Gorlin-Goltz syndrome with advanced BCC or numerous non-advanced BCC lesions, who may have been previously treated with sonic hedgehog pathway inhibitors [12] . The study started in June 2012 but was terminated by the sponsor in April 2017 due to the high percentage of patients who discontinued treatment (but not due to safety aspects). The authors summarised the treatment in the C1 group containing 77 patients and C2 containing 144 patients; ORR (95% CI) in C1 group was 68% (56-78), CR 45% (35/77), PR 22% (17/77), while in the C2 group it was 61%, 60% (86/144), and 1% (2/144), respectively. There were adverse reaction events in 82% (63/77) of patients in the C1 group and in 15% (22/144) in the C2 group, and serious adverse events in 14% (11/77) and 8% of patients (11/144), respectively. Interestingly, SCC (squamous cell carcinoma) was found only in the C2 group (64% of patients; 7/11).
In 2014, based on results of the expanded access study (EAS), Chang et al. evaluated the effectiveness of treatment of 95 patients (58.9% -laBCC, 41% -mBCC), after duration of treatment 5.5 months (0.4-19.6), including four patients previously treated with vismodegib [11] . In Table 4 it can be observed that the group of patients with laBCC in the EAS study achieved results similar to those presented by the Polish group after six months of treatment. This consistence can be interpreted in light of the small number of patients who were treated for 12 months, so the majority of data from authors of this article relate to a group with a duration of treatment similar to the EAS.
The STEVIE study, the first results of which were published in 2015, involved 1277 patients treated with vismodegib, of whom 499 (468 with laBCC and 31 with mBCC) were evaluated in safety set and 482 (453 with laBCC and 29 with mBCC) in an efficacy set [5] . The median duration of treatment was 36.3 weeks (17.6-60.0) for laBCC and 52 weeks (23.3-76.0) for mBCC patients. Based on the investigators assessment, overall response (OR) was found in 302 (66.7%, 62.1-71.0) of 453 laBCC patients, including 153 complete responses (CR) and 149 partial responses (PR). In total 11 (37.9%, 20.7-57.7) out of 29 mBCC patients responded to the treatment (OR), with two (7%) and nine (31%) patients receiving complete and partial response, respectively. In total 400 (80%) patients discontinued the study: 36% due to adverse reactions, 14% due to disease progression, and 10% based on the patient's decision. The safety profile was comparable to that in the ERIVANCE study. Of note, there were far fewer adverse reactions reported among patients in the Polish group compared to 98-100% of patients from the studies cited above (Table 5 ), and none of the patients discontinued the treatment due to AEs occurrence. Based on the data from the STEVIE and ERIVANCE studies, it is known that the average time to onset of adverse reactions varies depending on its nature (2.8 months for muscle cramps, 5.5 months for alopecia, and 6.5 months for dysgeusia) and account for two months on average [4, 5] . Hence, the short duration of treatment and the small number of Polish patients could be an explanation for these discrepancies. The concentration of these patients in three centres with extensive experience in the treatment of skin cancers is important for the reported results of the group of patients examined by the authors of this article.
In 2016 Chang et al. evaluated the effectiveness of treatment of patients with Gorlin-Goltz syndrome, qualified as laBCC or mBCC in the ERIVANCE and 
